The Latest Advances in Liquid Biopsy for Lung Cancer-a Narrative Review

Overview

Journal Transl Lung Cancer Res

Date 2024 Dec 13

PMID 39669995

Authors

Wei She

Yago Garitaonaindia

Yun Lin

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Liquid biopsy has emerged as a transformative approach in the diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated overview of the latest advancements in liquid biopsy for lung cancer, highlighting the key developments and their clinical implications.

Methods: A comprehensive literature search was conducted using databases, such as PubMed, Embase, and Web of Science, covering the period from January 2018 to July 2024. The search terms included "liquid biopsy", "lung cancer", "circulating tumor DNA", "circulating tumor cells", and "exosomes". Studies were selected based on their relevance, novelty, and impact on the field.

Key Content And Findings: The review discusses recent innovations in liquid biopsy technologies, including improvements in the sensitivity and specificity of these technologies, and the role of various biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, circulating tumor RNA (ctRNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and plasma protein biomarkers, in early detection, prognosis, and personalized therapy. It also examines challenges and future directions for integrating liquid biopsy into routine clinical practice.

Conclusions: Liquid biopsy represents a promising non-invasive diagnostic tool for lung cancer and has significant potential to enhance patient outcomes. It is anticipated that continued research and technological advancements will further refine its clinical utility, potentially transforming the landscape of lung cancer management.

References

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

Welsch E, Holzer B, Schuster E, Fabikan H, Weinlinger C, Hauptmann-Repitz E . Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation. Int J Cancer. 2024; 154(12):2189-2199. DOI: 10.1002/ijc.34886. View

Ye Y, Zhang Y, Luo Y, Xu A, Ji L . Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing. Am J Cancer Res. 2024; 14(2):655-678. PMC: 10915312. View

Wang Y, Zhang H, Li H, Xiong J, Wang J, Huang Y . Application of tumor-educated platelets as new fluid biopsy markers in various tumors. Clin Transl Oncol. 2022; 25(1):114-125. DOI: 10.1007/s12094-022-02937-1. View

Chen Y, Zitello E, Guo R, Deng Y . The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer. Clin Transl Med. 2021; 11(4):e367. PMC: 8021541. DOI: 10.1002/ctm2.367. View

Ishiba T, Hoffmann A, Usher J, Elshimali Y, Sturdevant T, Dang M . Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018; 500(3):621-625. PMC: 9165692. DOI: 10.1016/j.bbrc.2018.04.120. View

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J . Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021; 20(1):131. PMC: 8504100. DOI: 10.1186/s12943-021-01428-1. View

Ernst S, van Marion R, Atmodimedjo P, de Jonge E, Mathijssen R, Paats M . Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS-Mutated NSCLC Treated With Sotorasib. J Thorac Oncol. 2024; 19(7):995-1006. DOI: 10.1016/j.jtho.2024.04.007. View

Zheng M, Li Y, Jiang B, Tu H, Tang W, Yang J . Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. J Thorac Oncol. 2019; 14(5):924-932. DOI: 10.1016/j.jtho.2019.01.007. View

10.

Li H, Du S, Dai J, Jiang Y, Li Z, Fan Q . Proteome-wide Mendelian randomization identifies causal plasma proteins in lung cancer. iScience. 2024; 27(2):108985. PMC: 10850776. DOI: 10.1016/j.isci.2024.108985. View

11.

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

12.

Shen X, Dai J, Guo L, Liu Z, Yang L, Gu D . Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis. NPJ Precis Oncol. 2024; 8(1):30. PMC: 10847465. DOI: 10.1038/s41698-024-00520-1. View

13.

Davies M, Sato T, Ashoor H, Hou L, Liloglou T, Yang R . Plasma protein biomarkers for early prediction of lung cancer. EBioMedicine. 2023; 93:104686. PMC: 10320232. DOI: 10.1016/j.ebiom.2023.104686. View

14.

Tan A, Lai G, Saw S, Chua K, Takano A, Ong B . Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer. 2024; 130(10):1758-1765. DOI: 10.1002/cncr.35263. View

15.

Tsai Y, Schlom J, Donahue R . Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. J Exp Clin Cancer Res. 2024; 43(1):82. PMC: 10944611. DOI: 10.1186/s13046-024-02969-1. View

16.

Bar J, Leibowitz R, Reinmuth N, Ammendola A, Jacob E, Moskovitz M . Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy. Front Immunol. 2024; 15:1364473. PMC: 10937428. DOI: 10.3389/fimmu.2024.1364473. View

17.

Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J . Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019; 9(7):2056-2070. PMC: 6485294. DOI: 10.7150/thno.28119. View

18.

Sanchez-Herrero E, Serna-Blasco R, Ivanchuk V, Garcia-Campelo R, Domine Gomez M, Sanchez J . NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Mol Oncol. 2021; 15(9):2363-2376. PMC: 8410554. DOI: 10.1002/1878-0261.13033. View

19.

Sol N, In t Veld S, Vancura A, Tjerkstra M, Leurs C, Rustenburg F . Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Rep Med. 2020; 1(7):100101. PMC: 7576690. DOI: 10.1016/j.xcrm.2020.100101. View

20.

Ntzifa A, Strati A, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E . Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Sci Rep. 2021; 11(1):2313. PMC: 7840727. DOI: 10.1038/s41598-021-82068-9. View